Kite collaborates to increase efficiency of CAR-T manufacture

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Urfinguss)
(Image: Getty/Urfinguss)

Related tags: CAR-T, Kite, Gilead, MaxCyte

MaxCyte announces a partnership with Kite to explore the use of flow electroporation technology to enable the non-viral cell engineering of CAR-T drug candidates.

MaxCyte announces a partnership with Kite to explore the use of flow electroporation technology to enable the non-viral cell engineering of CAR-T drug candidates.

The collaboration between MaxCyte and Kite, a Gilead subsidiary, will expand upon an existing deal announced on November 12, 2018.

The original deal was signed for the same purpose: to use MaxCyte proprietary flow electroporation technology platform for non-viral cell engineering.

With the updated deal, Kite will have access to use the platform in order to develop up to 10 chimeric antigen receptor (CAR)-T drug candidates.

 MaxCyte will receive development and approval milestones, as well as sales-based payments and licensing fees. Other financial details of the deal were not released.

"We're excited to take our relationship with Kite further into product development, providing the company the ability to leverage MaxCyte's versatile cell engineering platform to enable the power of gene-editing for clinical and commercial development of critical new CAR-T therapeutics,"​ said Doug Doerfler, CEO of MaxCyte.

Improving CAR-T production

MaxCyte’s flow electroporation technology uses an electrical charge to produce the reversible permeability of cell membranes. This allows for the transfer of molecules, such as nucleic acids and proteins, into the cells thereby creating cell therapies.

According to MaxCyte, the production method is scalable from small-scale R&D to large-scale cell-engineering for global patient treatment.

The ability to improve on existing CAR-T production methods could be significant, as they are currently expensive to produce and, as has been found by its rival, can be unpredictable in creating therapies to the correct specification​.

Related news

Show more

Related products

show more

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers

Follow us

Products

View more

Webinars